A Prospective Cohort Study of Periostin As a Serum Biomarker in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib

Overview

Journal Sci Rep

Specialty Science

Date 2023 Dec 27

PMID 38151520

Authors

Masaki Okamoto

Kiminori Fujimoto

Takeshi Johkoh

Atsushi Kawaguchi

Hiroshi Mukae

Noriho Sakamoto

Takashi Ogura

Satoshi Ikeda

Yasuhiro Kondoh

Yasuhiko Yamano

Kosaku Komiya

Kenji Umeki

Hirotaka Nishikiori

Yoshinori Tanino

Toru Tsuda

Naoki Arai

Masamichi Komatsu

Susumu Sakamoto

Kazuhiro Yatera

Yoshikazu Inoue

Yasunari Miyazaki

Seishu Hashimoto

Yasuo Shimizu

Hironao Hozumi

Hiroshi Ohnishi

Tomohiro Handa

Noboru Hattori

Tomoo Kishaba

Motoyasu Kato

Minoru Inomata

Hiroshi Ishii

Naoki Hamada

Satoshi Konno

Yoshiaki Zaizen

Arata Azuma

Takafumi Suda

Kenji Izuhara

Tomoaki Hoshino

Affiliations

Soon will be listed here.

Abstract

This study investigated the utility of periostin, a matricellular protein, as a prognostic biomarker in patients with idiopathic pulmonary fibrosis (IPF) who received nintedanib. Monomeric and total periostin levels were measured by enzyme-linked immunosorbent assay in 87 eligible patients who participated in a multicenter prospective study. Forty-three antifibrotic drug-naive patients with IPF described in previous studies were set as historical controls. Monomeric and total periostin levels were not significantly associated with the change in forced vital capacity (FVC) or diffusing capacity of the lungs for carbon monoxide (D) during any follow-up period. Higher monomeric and total periostin levels were independent risk factors for overall survival in the Cox proportional hazard model. In the analysis of nintedanib effectiveness, higher binarized monomeric periostin levels were associated with more favorable suppressive effects on decreased vital capacity (VC) and D in the treatment group compared with historical controls. Higher binarized levels of total periostin were associated with more favorable suppressive effects on decreased D but not VC. In conclusion, higher periostin levels were independently associated with survival and better therapeutic effectiveness in patients with IPF treated with nintedanib. Periostin assessments may contribute to determining therapeutic strategies for patients with IPF.

Citing Articles

Exercise-Induced Oxygen Desaturation and Outcomes After Nintedanib Therapy for Fibrosing Interstitial Lung Disease in Patients Without Dyspnea.

Okamoto M, Yanagihara T, Fujimoto K, Chikasue T, Tabata K, Zaizen Y J Clin Med. 2025; 13(24.

PMID: 39768788 PMC: 11727922. DOI: 10.3390/jcm13247865.

Diagnosis of Lung Cancer Through Exhaled Breath: A Comprehensive Study.

Gashimova E, Temerdashev A, Perunov D, Porkhanov V, Polyakov I Mol Diagn Ther. 2024; 28(6):847-860.

PMID: 39299985 DOI: 10.1007/s40291-024-00744-8.

References

Ley B, Bradford W, Vittinghoff E, Weycker D, du Bois R, Collard H . Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016; 194(6):711-8. PMC: 5027229. DOI: 10.1164/rccm.201508-1546OC. View

Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y . Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000; 162(3 Pt 1):1109-14. DOI: 10.1164/ajrccm.162.3.9910080. View

Yamaguchi Y, Ono J, Masuoka M, Ohta S, Izuhara K, Ikezawa Z . Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br J Dermatol. 2012; 168(4):717-25. DOI: 10.1111/bjd.12117. View

Yoshikawa T, Otsuka M, Chiba H, Ikeda K, Mori Y, Umeda Y . Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2020; 20(1):27. PMC: 6995128. DOI: 10.1186/s12890-020-1060-y. View

Nukui Y, Miyazaki Y, Masuo M, Okamoto T, Furusawa H, Tateishi T . Periostin as a predictor of prognosis in chronic bird-related hypersensitivity pneumonitis. Allergol Int. 2019; 68(3):363-369. DOI: 10.1016/j.alit.2019.02.007. View

Flaherty K, Mumford J, Murray S, Kazerooni E, Gross B, Colby T . Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003; 168(5):543-8. DOI: 10.1164/rccm.200209-1112OC. View

Kreuter M, Lee J, Tzouvelekis A, Oldham J, Molyneaux P, Weycker D . Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021; 204(1):74-81. PMC: 8437112. DOI: 10.1164/rccm.202003-0669OC. View

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Ryerson C, Lederer D . Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5):e44-e68. DOI: 10.1164/rccm.201807-1255ST. View

Organ L, Duggan A, Oballa E, Taggart S, Simpson J, Kangombe A . Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. Respir Res. 2019; 20(1):148. PMC: 6624898. DOI: 10.1186/s12931-019-1118-7. View

10.

Salisbury M, Conoscenti C, Culver D, Yow E, Neely M, Bender S . Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020; 17(11):1413-1423. PMC: 7640723. DOI: 10.1513/AnnalsATS.201912-880OC. View

11.

Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T . Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest. 2021; 160(5):1751-1763. DOI: 10.1016/j.chest.2021.06.049. View

12.

Uchida M, Shiraishi H, Ohta S, Arima K, Taniguchi K, Suzuki S . Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012; 46(5):677-86. PMC: 4304367. DOI: 10.1165/rcmb.2011-0115OC. View

13.

Karampitsakos T, Juan-Guardela B, Tzouvelekis A, Herazo-Maya J . Precision medicine advances in idiopathic pulmonary fibrosis. EBioMedicine. 2023; 95:104766. PMC: 10469771. DOI: 10.1016/j.ebiom.2023.104766. View

14.

Inoue Y, Kaner R, Guiot J, Maher T, Tomassetti S, Moiseev S . Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest. 2020; 158(2):646-659. DOI: 10.1016/j.chest.2020.03.037. View

15.

Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M . Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006; 11(2):164-8. DOI: 10.1111/j.1440-1843.2006.00834.x. View

16.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

17.

Mogulkoc N, Brutsche M, Bishop P, Greaves S, Horrocks A, Egan J . Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med. 2001; 164(1):103-8. DOI: 10.1164/ajrccm.164.1.2007077. View

18.

Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S . Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006; 118(1):98-104. DOI: 10.1016/j.jaci.2006.02.046. View

19.

Ryerson C, Vittinghoff E, Ley B, Lee J, Mooney J, Jones K . Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2013; 145(4):723-728. DOI: 10.1378/chest.13-1474. View

20.

Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman W, Lee C, Pugashetti J . Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest. 2020; 158(4):1526-1534. PMC: 7545483. DOI: 10.1016/j.chest.2020.04.066. View